{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:58:05Z","timestamp":1782255485817,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T00:00:00Z","timestamp":1591401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T00:00:00Z","timestamp":1591401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s40744-020-00209-4","type":"journal-article","created":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T11:02:43Z","timestamp":1591441363000},"page":"553-580","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study"],"prefix":"10.1007","volume":"7","author":[{"given":"Peter","family":"Nash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J.","family":"Kivitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Covarrubias-Cobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"FitzGerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dona","family":"Fleishaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Ann","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujatha","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Fallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Bel\u00e9n","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith S.","family":"Kanik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,6]]},"reference":[{"key":"209_CR1","first-page":"ii14","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64:ii14\u2013ii17.","journal-title":"Ann Rheum Dis"},{"key":"209_CR2","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:957\u201370.","journal-title":"N Engl J Med"},{"key":"209_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/acr.23789","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, et al. Special Article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Care Res (Hoboken). 2019;71:2\u201329.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"209_CR4","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75:499\u2013510.","journal-title":"Ann Rheum Dis"},{"key":"209_CR5","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68:1060\u201371.","journal-title":"Arthritis Rheumatol"},{"key":"209_CR6","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377:1537\u201350.","journal-title":"N Engl J Med"},{"key":"209_CR7","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377:1525\u201336.","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"209_CR8","first-page":"682","volume":"76","author":"P Nash","year":"2017","unstructured":"Nash P, Coates LC, Kivitz AJ, et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, up to 24 months in patients with active psoriatic arthritis: interim data from OPAL Balance, an open-label, long-term extension study. Ann Rheum Dis. 2017;76(Suppl 2):682.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 10","key":"209_CR9","first-page":"840","volume":"69","author":"P Nash","year":"2017","unstructured":"Nash P, Coates LC, Kivitz AJ, et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the second interim analysis of OPAL Balance, an open-label, long-term extension study. Arthritis Rheumatol. 2017;69(Suppl 10):840\u20131.","journal-title":"Arthritis Rheumatol"},{"key":"209_CR10","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665\u201373.","journal-title":"Arthritis Rheum"},{"key":"209_CR11","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1002\/art.1780391210","volume":"39","author":"DO Clegg","year":"1996","unstructured":"Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996;39:2013\u201320.","journal-title":"Arthritis Rheum."},{"key":"209_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69:48\u201353.","journal-title":"Ann Rheum Dis"},{"key":"209_CR13","unstructured":"World Health Organization. Global tuberculosis report 2019. 2019. https:\/\/www.who.int\/tb\/publications\/global_report\/en\/. Accessed 6 Nov 2019."},{"key":"209_CR14","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","volume":"76","author":"SB Cohen","year":"2017","unstructured":"Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017;76:1253\u201362.","journal-title":"Ann Rheum Dis."},{"key":"209_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","volume":"21","author":"J Wollenhaupt","year":"2019","unstructured":"Wollenhaupt J, Lee EB, Curtis JR, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019;21:89.","journal-title":"Arthritis Res Ther."},{"key":"209_CR16","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1002\/art.38745","volume":"66","author":"KL Winthrop","year":"2014","unstructured":"Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66:2675\u201384.","journal-title":"Arthritis Rheumatol"},{"key":"209_CR17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.semarthrit.2016.05.014","volume":"46","author":"C Charles-Schoeman","year":"2016","unstructured":"Charles-Schoeman C, Wicker P, Gonzalez-Gay MA, et al. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. Semin Arthritis Rheum. 2016;46:261\u201371.","journal-title":"Semin Arthritis Rheum"},{"key":"209_CR18","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1136\/ard.2008.092767","volume":"68","author":"PJ Mease","year":"2009","unstructured":"Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis. 2009;68:702\u20139.","journal-title":"Ann Rheum Dis"},{"key":"209_CR19","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1136\/ard.2008.102103","volume":"68","author":"GR Burmester","year":"2009","unstructured":"Burmester GR, Mease P, Dijkmans BA, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis. 2009;68:1863\u20139.","journal-title":"Ann Rheum Dis"},{"key":"209_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/acr.23111","volume":"69","author":"A Kavanaugh","year":"2017","unstructured":"Kavanaugh A, Mease PJ, Reimold AM, et al. Secukinumab for long-term treatment of psoriatic arthritis: a two-year followup from a Phase III, randomized, double-blind placebo-controlled study. Arthritis Care Res (Hoboken). 2017;69:347\u201355.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"209_CR21","doi-asserted-by":"publisher","first-page":"e000942","DOI":"10.1136\/rmdopen-2019-000942","volume":"5","author":"JR Curtis","year":"2019","unstructured":"Curtis JR, Mariette X, Gaujoux-Viala C, et al. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials. RMD Open. 2019;5:e000942.","journal-title":"RMD Open"},{"key":"209_CR22","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/art.40780","volume":"71","author":"R van Vollenhoven","year":"2019","unstructured":"van Vollenhoven R, Lee EB, Strengholt S, et al. Evaluation of the short-, mid-, and long-term effects of tofacitinib on lymphocytes in patients with rheumatoid arthritis. Arthritis Rheumatol. 2019;71:685\u201395.","journal-title":"Arthritis Rheumatol"},{"key":"209_CR23","unstructured":"US Food and Drug Administration. XELJANZ\u00ae (tofacitinib): highlights of prescribing information. 2019. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=959. Accessed 08 Apr 2020."},{"key":"209_CR24","unstructured":"European Medicines Agency. Xeljanz (tofacitinib)\u2014summary of product characteristics. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xeljanz-epar-product-information_en.pdf. Accessed 29 Oct 2019."}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-020-00209-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-020-00209-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-020-00209-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T16:29:51Z","timestamp":1715185791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-020-00209-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,6]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["209"],"URL":"https:\/\/doi.org\/10.1007\/s40744-020-00209-4","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,6]]},"assertion":[{"value":"21 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}